Abstract:Cancer continues to be a major global public health concern and one of the foremost causes of death. Delays in the diagnosis and cure may cause an increase in advanced stage disease and mortality. The most common cancer found in women currently is breast carcinoma. Breast carcinoma has surpassed lung carcinoma and currently represents the chief type of cancer diagnosed (2.3 million new cases, which amount to 11.7% of all cancer cases). In addition, by 2040, the incidence will increase by more than 46% as per the estimates of GLOBOCAN. Triple-negative breast cancer (TNBC) represents a highly aggressive and invasive subtype of breast cancer, characterized by rapid progression, short response time to the available treatment, and poor clinical results. Thus, it is very crucial to develop novel diagnostic tools and therapeutics with good efficacy. A majority of cancers display malfunction along the p53 pathway. Moreover, p53 not only loses its function but is also prone to misfolding and aggregation, leading to formation of amyloid aggregates as well. Research is being carried out to find ways to restore the normal action and expression of p53. Here, we have explored PhiKan-083 for its possible stabilizing effect on p53 in order to address the problem with its misfolding. Thus, examining the analogs of PhiKan-083 that have a role in p53 stability will help update our understanding of cancer progression and may expedite the progress of new anticancer treatments. We anticipate that the drug molecules and their analogs targeting p53 aggregation may be used in combination with other anticancer compounds to solve the problem with p53 aggregation. In this study, by employing ADMET analysis, the compounds were screened, and we further examined the chosen compounds with the help of molecular docking. By using databases like UALCAN, TIMER, GEPIA, and PredictProtein, we investigated TP53's expression pattern and prognostic relevance in various cancer settings.

Mechanism Of Initiation Of Aggregation Of P53 Revealed By Phi-Value Analysis

Kinetic Mechanism of P53 Oncogenic Mutant Aggregation and Its Inhibition

First-Order Rate-Determining Aggregation Mechanism Of P53 And Its Implications

Multisite Aggregation Of P53 And Implications For Drug Rescue

Propagation of Aggregated P53: Cross-reaction and Coaggregation Vs. Seeding

Self-Aggregation And Coaggregation Of The P53 Core Fragment With Its Aggregation Gatekeeper Variant

Gain of Function of Mutant P53 by Coaggregation with Multiple Tumor Suppressors

Full-atomistic Molecular Dynamics Analysis of p53 Active Tetramer

Mechanistic Insight into the Destabilization of P53td Tetramer by Cancer-Related R337H Mutation: a Molecular Dynamics Study.

Multiscale simulations reveal the driving forces of p53C phase separation accelerated by oncogenic mutations

Free Energy Profile and Kinetics of Coupled Folding and Binding of the Intrinsically Disordered Protein p53 with MDM2

Unraveling The Allosteric Mechanism Of Four Cancer-Related Mutations In The Disruption Of P53-Dna Interaction

Activation and control of p53 tetramerization in individual living cells

The molecular mechanism of action of methylene quinuclidinone and its effects on the structure of p53 mutants

Conformational Stability and Dynamics of the Cancer‐associated Isoform Δ133p53β Are Modulated by P53 Peptides and P53‐specific DNA

In Silico Screening, Molecular Dynamics Simulation and Binding Free Energy Identify Single-Point Mutations That Destabilize p53 and Reduce Binding to DNA

Kinetic and thermodynamic effects of phosphorylation on p53 binding to MDM2

Targeting p53 misfolding conundrum by stabilizing agents and their analogs in breast cancer therapy: a comprehensive computational analysis

Modulation of the p53-MDM2 Interaction by Phosphorylation of Thr18: A Computational Study

Catalytic Nucleation of Amyloid Beta and Hen Egg White Fibrils, and p53 Oligomerization

Activation of p53: how phosphorylated Ser15 triggers sequential phosphorylation of p53 at Thr18 by CK1δ